Ajanta Pharma signs in-licensing pact with Biocon for marketing semaglutide in 26 countries

Semaglutide is indicated to improve glycaemic control in adults and is an active ingredient in brands like Ozempic. Shares of Ajanta Pharma ended 1.14% in the red in the session on Tuesday. The stock has fallen close to 11% in the year so far.

Leave a Reply

Your email address will not be published. Required fields are marked *